Dr. Maha A. Assi, MD
Infectious Disease (Infectious Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 670
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Infectious Disease Physician primary
KS license 04-29896
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ascension Via Christi Hospitals Wichita, Inc. Wichita, KS
- Wesley Medical Center Wichita, KS
- Salina Regional Health Center Salina, KS
- William Newton Hospital Winfield, KS
- Centura St. Catherine-Dodge City Dodge City, KS
Medical groups
- Ascension Via Christi Hospitals Wichita Inc (121 clinicians)
- Infectious Disease Consultants, P.a. (23 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 670
- Services billed
- 77,881
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Injection, daptomycin, 1 mg | 42,700 | 25 |
| Injection, immune globulin (bivigam), 500 mg | 3,590 | 37 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 1,824 | 360 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 699 | 193 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 296 | 266 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 247 | 114 |
| Injection, ceftriaxone sodium, per 250 mg | 244 | 20 |
| Injection, ertapenem sodium, 500 mg | 162 | 34 |
| Established patient office or other outpatient visit, 30-39 minutes | 125 | 93 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 85 | 46 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Methenamine Hippurate Other prescribers in Wichita, KS | 109 |
| Cephalexin Other prescribers in Wichita, KS | 50 |
| Meropenem | 44 |
| Cefepime Hcl | 41 |
| Daptomycin | 35 |
| Vancomycin Hcl | 32 |
| Sodium Chloride (0.9 % sodium chloride) Other prescribers in Wichita, KS | 29 |
| Ceftriaxone (ceftriaxone sodium) Other prescribers in Wichita, KS | 27 |
| Doxycycline Hyclate Other prescribers in Wichita, KS | 26 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Wichita, KS | 26 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 18 payments worth $580 in total to this clinician.
| Novo Nordisk Inc | $121 |
|---|---|
| Amgen Inc. | $110 |
| Takeda Pharmaceuticals U.S.A., Inc. | $83.88 |
| Hospira, Inc. | $64.75 |
| Pfizer Inc. | $50.84 |
| AbbVie Inc. | $31.69 |
| Grifols USA, LLC | $30.20 |
| Gilead Sciences, Inc. | $22.91 |
| Food and Beverage | $580 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $13,536 in research payments for these studies, mostly to the institutions running them.
- ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
Mannkind Corporation · Terminated · NCT06418711 - REBYOTA™ Prospective Registry
Ferring Pharmaceuticals As · Completed · NCT05835219
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.